GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seagen Inc (NAS:SGEN) » Definitions » Accounts Receivable

Seagen (Seagen) Accounts Receivable : $632 Mil (As of Sep. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Seagen Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Seagen's accounts receivables for the quarter that ended in Sep. 2023 was $632 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Seagen's Days Sales Outstanding for the quarter that ended in Sep. 2023 was 88.85.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Seagen's Net-Net Working Capital per share for the quarter that ended in Sep. 2023 was $4.73.


Seagen Accounts Receivable Historical Data

The historical data trend for Seagen's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seagen Accounts Receivable Chart

Seagen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 146.28 236.00 324.99 389.26 501.91

Seagen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 486.76 501.91 495.78 586.05 631.56

Seagen Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Seagen Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Seagen's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=631.555/648.65*91
=88.85

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Seagen's accounts receivable are only considered to be worth 75% of book value:

Seagen's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1236.986+0.75 * 631.555+0.5 * 531.188-1083.84
-0-0)/188.628
=4.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Seagen Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Seagen's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Seagen (Seagen) Business Description

Traded in Other Exchanges
N/A
Address
21823 - 30th Drive South East, Bothell, WA, USA, 98021
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Executives
David R Epstein director, officer: Chief Executive Officer INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Vaughn B Himes officer: See Remarks C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Charles R Romp officer: EVP, Commercial 21823 30TH DRIVE SE, BOTHELL WA 98021
Roger D Dansey officer: See Remarks 21823 30TH DRIVE SE, BOTHELL WA 98021
Jean I Liu officer: GC & EVP, Legal Affairs 21823 30TH DRIVE SE, BOTHELL WA 98021
Todd E Simpson officer: Chief Financial Officer
Daniel G Welch director 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
Sandra M Swain director 21823 30TH DRIVE SE, BOTHELL WA 98021
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Clay B Siegall director, officer: President and CEO 21823 30TH DR SE, BOTHELL WA 98021
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014

Seagen (Seagen) Headlines

From GuruFocus

Seagen Stockholders Approve Acquisition by Pfizer

By Business Wire Business Wire 05-30-2023

Seagen to Present at the Cowen 43rd Annual Health Care Conference

By Business Wire Business Wire 02-27-2023